Alzheimer's Disease International's 2026 World Alzheimer Report documents a rapid expansion in dementia drug and non-pharmacological trials, alongside persistent gaps in who actually enrolls. Participants remain skewed toward higher-income, predominantly White, relatively healthy populations, which constrains how confidently results transfer to the people who carry the greatest dementia burden. Representativeness, not trial volume alone, determines whether emerging therapies translate into population-level cognitive longevity.
Key Points
- Dementia trial numbers rising across drug and non-drug interventions
- Enrolled populations poorly reflect global dementia burden and comorbidity
- Narrow recruitment limits generalizability of emerging treatment evidence
Longevity Analysis
Evidence that cannot be applied to the patient in front of you is incomplete evidence, and the dementia field now faces that limitation at scale. Cognitive decline is rarely a single-pathway event — vascular health, metabolic regulation, inflammatory load, and sleep architecture all shape trajectory, and these vary sharply across the populations currently absent from trial rosters. Until enrollment reflects that heterogeneity, clinicians interpreting trial data for diverse patients are extrapolating rather than applying, and prevention strategies built on modifiable risk remain the more reliable near-term lever.
Original published by The Lancet Healthy Longevity, by The Lancet Healthy Longevity.